Muscular Dystrophy Association (MDA) Clinical & Scientific Conference 2026

Dr. David Arnold, Executive Director of the NextGen Precision Health Initiative, Professor of Physical Medicine and Rehabilitation, Co-Director of Tom and Anne Smith MD/PhD Program, Director of the Center for Translational Neurogenetics at University of Missouri School of Medicine and SYNAPSE-CMT investigator presented a poster and late-breaking oral presentation describing safety and efficacy data from its Phase 2a SYNAPSE-CMT study evaluating ignaseclant (formerly known as NMD670) in patients living with Charcot-Marie-Tooth disease (CMT) types 1 or 2 at the 2026 MDA Clinical & Scientific Conference held in Orlando, Florida from March 8-11, 2026. In addition, NMD Pharma presented an update on the ongoing SYNAPSE-MG study evaluating ignaseclant in generalised myasthenia gravis patients who are AChR or MuSK autoantibody positive in an oral presentation.